WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, … WebMar 10, 2024 · Mar 10, 2024 7:32AM EST G ain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, announced terms for its IPO on Wednesday. The Bethesda,...
Gain Therapeutics - Home
WebMar 22, 2024 · Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have … Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target … Gain is utilizing its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) … Parkinson’s disease is a neurodegenerative disorder that affects more than 6 million … Company expects completion of IND-enabling studies of GT-02287 in H1 … GAIN THERAPEUTICS INC. 4800 Montgomery Lane Ste 220 Bethesda, … Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about … Gain is utilizing its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) … International Congress of Parkinson’s Disease and Movement Disorders 2024 … International Congress of Parkinson’s Disease and Movement Disorders 2024 … WebAug 3, 2024 · The market expects Gain Therapeutics, Inc. (GANX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended … pink cereal spoon
Gain Therapeutics - Brief Introduction
WebNov 11, 2024 · Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Presentations August, 2024 Corporate Presentation WebApr 13, 2024 · Bellerophon Therapeutics (BLPH) closed the most recent trading day at $10.98, moving -1.08% from the previous trading session. This change lagged the S&P 500's daily gain of 1.33%. WebJul 21, 2024 · BETHESDA, Md., July 21, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on developing first-in-class medicines that target novel allosteric binding... pink cereal box